Leios & BNC Korea Target Asia's Aesthetics Market with New Fat Reducer

LA JOLLA, Calif. – January 26, 2026 – Leios Therapeutics, a clinical-stage biotech company, has announced a major strategic collaboration with BNC Korea, a leading South Korean aesthetics firm. The deal grants BNC Korea the rights to develop and commercialize 10XB-101, Leios’s investigational injectable for focal fat reduction, across a vast swathe of Asia and Eastern Europe, coupled with a significant equity investment in the California-based company.

This partnership marks a critical step for Leios, providing a clear pathway into the booming Asian aesthetics market, which is projected to be the fastest-growing region globally. The agreement covers South Korea, Taiwan, Singapore, Indonesia, Thailand, Vietnam, Russia, Belarus, and Kazakhstan, positioning 10XB-101 for a substantial international launch.

“We are delighted to enter this strategic partnership with BNC Korea for 10XB-101, marking a significant milestone for Leios Therapeutics,” said Ted White, Chief Executive Officer of Leios Therapeutics. “BNC Korea’s leadership in the aesthetics market, deep regional expertise, and outstanding commercialization capabilities make them an ideal partner to help bring 10XB-101 to market.”

A Strategic Push into Asia's Aesthetic Frontier

The collaboration is strategically timed to capitalize on the explosive growth of the aesthetic medicine market in Asia. The Asia-Pacific region's non-invasive fat reduction market is forecast to grow at a compound annual growth rate (CAGR) of over 16%, with some estimates projecting it as high as 20% through 2032. South Korea, a global trendsetter in aesthetics, is a cornerstone of the deal. Its domestic aesthetic devices market alone is expected to climb from approximately $515 million in 2025 to over $865 million by 2031, with body contouring procedures representing nearly 30% of that value.

BNC Korea, listed on the KOSDAQ exchange, is a formidable partner for this endeavor. Founded in 2007, the company has built a strong reputation as a manufacturer of dermal fillers and other medical products based on biomaterials like hyaluronic acid. Their established distribution network and commercial success in the highly competitive K-beauty landscape provide the infrastructure needed to navigate complex regulatory environments and drive market adoption.

“We are pleased to partner with Leios Therapeutics on 10XB-101, a promising candidate in the rapidly expanding body contouring market,” stated Choi Wan-gyo, CEO of BNC Korea, highlighting the product's potential to address unmet needs in the sector.

The Science Behind 10XB-101: A 'Best-in-Class' Contender

At the heart of the deal is 10XB-101, a minimally invasive injectable treatment designed to be a best-in-class option for reducing localized fat deposits. The product is a novel formulation of polidocanol, a substance already approved for other medical uses, which Leios has repurposed for aesthetic body contouring. Its mechanism involves the targeted destruction of fat cell membranes upon injection, with the body naturally absorbing the resulting cellular debris. Critically, the treatment is also believed to induce mild fibrosis, which helps to firm and tighten the skin in the treated area—a significant advantage for indications like submental fat, or a “double chin.”

The promise of 10XB-101 is backed by compelling clinical data. In a Phase 2b study, the treatment demonstrated remarkable efficacy. Between 64% and 70% of patients receiving higher doses achieved a significant, physician- and patient-rated improvement of two grades or more, compared to 0% in the placebo group. Perhaps more importantly, the product showed what Leios describes as a “pristine safety profile.”

This positions 10XB-101 as a strong competitor to existing treatments. Its primary injectable rival, deoxycholic acid (marketed as Kybella), is known to be effective but is often associated with significant side effects like pain, prolonged swelling, and bruising. In contrast, clinical data for 10XB-101 suggests excellent tolerability with minimal injection site reactions, potentially offering a more comfortable patient experience and less downtime. This favorable profile could allow it to capture market share not only from other injectables but also from non-invasive device-based treatments like cryolipolysis (CoolSculpting) and radiofrequency (RF) systems.

Fueling Growth Through Strategic Investment

Beyond the licensing rights, BNC Korea has made a strategic equity investment in Leios Therapeutics. While the financial specifics were not disclosed, the infusion of capital is a powerful endorsement of Leios’s technology and clinical progress. For a clinical-stage company, such investments are vital for funding the expensive later stages of clinical trials and scaling up operations.

As CEO Ted White noted, “The strategic investment further validates the potential of our pipeline, strengthens our balance sheet and supports the advancement of our clinical development program and long-term growth strategy.” This type of partnership, where a larger commercial entity invests in an innovator in exchange for regional rights, is a classic biotech growth strategy that de-risks development and accelerates the path to revenue.

This financial backing, facilitated by Vault Advisors, provides Leios with the runway to continue its development programs while BNC Korea begins the process of bringing 10XB-101 to its designated territories.

Navigating the Path to Market

The agreement marks the beginning of the next crucial phase: securing regulatory approval. BNC Korea will now spearhead the effort to navigate the distinct regulatory bodies in each of the nine territories, including South Korea’s Ministry of Food and Drug Safety (MFDS), Taiwan’s TFDA, and Singapore’s HSA. Each country has its own rigorous process for approving new medical products, requiring extensive submission of clinical, safety, and manufacturing data.

However, the development pathway for 10XB-101 may offer an advantage. Because it is based on polidocanol, a well-understood compound, it could potentially benefit from streamlined regulatory approaches similar to the FDA's 505(b)(2) pathway in the U.S., which allows developers to leverage existing data. This could potentially shorten timelines and reduce the cost of gaining market authorization.

The partnership effectively combines Leios's scientific innovation with BNC Korea's regional regulatory expertise and commercial muscle. As BNC Korea works to bring 10XB-101 to patients in Asia and beyond, Leios can focus on advancing its pipeline in other global markets, creating a synergistic relationship poised to make a significant impact on the international aesthetics landscape.